FDA Approved: ZEMPLAR — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Zemplar (paricalcitol) filed by AbbVie Inc., approving an update to the product labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperparathyroidism

Drugs mentioned

• Zemplar (Paricalcitol)

Snippet

SUPPL AP for ZEMPLAR (PARICALCITOL)